Overview

Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis

Status:
Unknown status

Trial end date:
2019-06-14

Target enrollment:

Participant gender:

Summary

This study aims to evaluate more objectively, through an imaging technique such as ultrasound, changes in joints and entheses of patients with active psoriatic arthritis (PAs) who will start treatment with Apremilast after the failure of other therapies such as synthetic DMARD (metrotrexato , Leflunomide ...). The hypothesis of the study is that the technique of ultrasound can demonstrate the efficacy of Apremilast in the treatment of patients with active PAs

Phase:

Phase 3

Details

Lead Sponsor:

Hospital Universitari Vall d'Hebron Research Institute

Collaborator:

Celgene Corporation

Treatments:

Apremilast
Thalidomide